Case Study
Me-Better Optimization — BGM1812,
A Novel Amylin-like Protein Analog
Highlights
With in 6 months, 13 molecules were designed to develop BGM1812 — an AI-designed
and molecular dynamics simulation-optimized novel
amylin-like protein analog with higher potency than existing clinical drugs. Results
were published in J. Med. Chem. (2025) and presented at ADA.
Project Overview
Client
Brightgene
Objective
To optimize the amylin-like protein analog for enhanced stability, reduced aggregation, and improved receptor potency.
Main Challenge
How to determine the target sites in the structure fast for modification.
Design Strategy /
Approach
Approach
- Anti-aggregation Optimization: Molecular dynamics simulations showed that mutating the Ile(Me)24 site in Petrelintide to Gly(Me)24 significantly enhanced the anti-aggregation ability of the peptide (cited from J. Med. Chem. 2025, 68, 14, 14907–14918).
- Hydrophobic Interaction Enhancement: By strengthening key hydrophobic cage interactions, the BGM1812 molecule was developed within 6 months, significantly enhancing its hydrophobic interactions with only 13 molecules designed (cited from the same J. Med. Chem. literature above).
Key Results /
Milestones
Milestones
- Key Conclusions from In Vitro and In Vivo Tests: BGM1812 showed stronger cAMP agonist activity at both AMYR3 and CTR; compared with BGM1802, BGM1812 exhibited superior fat reduction efficacy.
- Research findings were published in J. Med. Chem. (2025 Jul 3).
View Article Details
Interested in how Divamics can accelerate
your next discovery project?
Contact Us
